跳至主要内容
临床试验/NCT06201780
NCT06201780招募中不适用

Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria

Sohag University1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2023年12月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
90
试验地点
1
主要终点
serum levels of janus kinase 1

研究概览

简要总结

Cholinergic Urticaria (CholU) is as a subtype of CIndU caused by an increase in the core body temperature, such as to activate the sweating reflex. It can occur in response to physical exercise, hot bathing and/or emotional stress. Clinically it appears as pinpointing and highly pruritic wheals with surrounding erythema, CholU can be accompanied by severe symptoms such as angioedema, respiratory symptoms or anaphylaxi CholU is frequently associated with atopic dermatitis (AD) The JAK-STAT is a mast cell (MC) signaling pathway activated downstream of IgE and IL-3 with important roles in MC homeostasis via regulation of proliferation, survival, and release of mediators. JAK-STAT activation is associated with polarization toward Th2, B cell isotype switching to IgE production, and IgE-dependent degranulation and cytokine release .

Because both IL-4 and IL-13 use the IL-4Rα as a receptor component, these cytokines activate any common signaling pathways. Both of these cytokines use Janus kinases (JAKs) to initiate signaling and activate signal transducer and activator of transcription-6 (STAT6), which is a transcription factor required for many of their biologic functions.

The non-receptor protein tyrosine kinases JAK1 and JAK3 associate with the IL-4Rα and γC, respectively. The binding of IL-4 to its receptor induces the transphosphorylation of JAK1 and JAK3, an event that activates these kinases and thereby initiates the early events of signal transduction .

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
15 Years 至 55 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • The study will include 45 adult patients complaining of CholU as well as 45 healthy controls.

排除标准

  • Patients with one or more of the following criteria will be excluded:
  • Pregnancy and lactation.
  • Patients with systemic diseases especially those with autoimmune diseases and infections.
  • Patients with skin diseases.
  • Patients on medications such as: antibiotics, non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, anticonvulsants, penicillin, combined oral contraceptives.
  • Patient refusal

结局指标

主要结局

serum levels of janus kinase 1

时间窗: 1 year

assessment of serum levels of janus kinase 1

次要结局

  • serum levels of janus kinase 2(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marwa Elsayed Mohamed

Resident-Dermatology department-sohag hospital university

Sohag University

研究点 (1)

Loading locations...

相似试验